Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells. Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding.
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Victories Over Cancer is about enabling those affected by cancer to enjoy more of life’s meaning full moments and making cancer more manageable. At Janssen, we're really thinking about the elimination of cancer, and we take a very deliberate approach to that.
Mouse models have advanced our understanding of immune function and disease in many ways but they have failed to account for the natural diversity in human immune responses.
Sanford Burnham Prebys Medical Discovery Institute has undertaken the first-ever comparative analysis of a newly emerging category of algorithms that mine genetic information in cancer databases by focusing on internal gene structure (subgene resolution algorithms), in contrast to classical approaches that focus on genes treated as single units.
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.
Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers.
Scientists at Karolinska Institutet in Sweden report that cancer cells and normal cells use different 'gene switches' in order to regulate the expression of genes that control growth.
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center
A cancer drug for patients with certain types of leukemia and lymphoma can also prevent reactions to some of the most common airborne allergies, according to a recent Northwestern Medicine study. The promising data from this pilot study could have greater implications for adults with food allergies.
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.
Scientists have described new results of a blood cancer study as 'outstanding' in tackling previously untreatable forms of chronic lymphocytic leukemia.
Scientists at The Wistar Institute have unveiled part of the protein complex that protects telomeres-;the ends of our chromosomes. The study, published online in Nature Communications, explains how a group of genetic mutations associated with this protein complex contributes to various cancers.
Researchers have discovered one of the reasons why broccoli may be good for your health.
Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues.
A very rare sub-type of Non-Hodgkin's Lymphoma, Waldenström's Macroglobulinemia affects approximately 1,500 - 2,000 people in the United States each year. While it is not curable, Waldenström's Macroglobulinemia is slow growing, and in many patients, manageable as a chronic disease.
An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer's or baker's yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.
The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer - Gliomas—the first in a series of patient education resources focused on Brain Cancer.
Leukemia is a disease in which each cell can exhibit different genetic traits, and now Swedish researchers have found a cheap way to examine the individual cells. Reported in Nature Communications, the breakthrough could transform leukemia treatment.
This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year.
In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy.